An NO Donor Approach to Neuroprotective and Procognitive Estrogen Therapy Overcomes Loss of NO Synthase Function and Potentially Thrombotic Risk

Medicine & Life Sciences

• desmethylarzoxifene 84%
• Selective Estrogen Receptor Modulators 82%
• Nitric Oxide Synthase 60%
• Nitric Oxide Synthase Type III 56%
• Estrogens 51%
• Anticoagulants 34%
• Long-Term Potentiation 28%
• Neuroprotection 26%
• Vasodilation 24%
• Estrogen Receptor Modulators 16%
• Vasodilator Agents 12%
• G-Protein-Coupled Receptors 12%
• Cholinergic Agents 11%
• Estrogen Receptors 11%
• Transgenic Mice 11%
• Endothelium 11%
• Therapeutics 10%
• Cognition 9%
• Breast 9%
• Memory 9%
• Oxygen 8%
• Breast Neoplasms 7%
• Glucose 7%
• Neurons 7%
• Bone and Bones 7%

Chemical Compounds

• Selective Estrogen Receptor Modulator 100%
• Thrombotic 96%
• Neuroprotective 79%
• Estrogen 66%
• Donor 42%
• Estrogen Receptor Modulator 28%
• Cholinergic 19%
• Probe 18%
• Glucose 11%
• Dioxygen 7%

Agriculture & Biology

• estrogen receptors 70%
• endothelial nitric oxide synthase 58%
• estrogens 56%
• therapeutics 48%
• anticoagulant activity 41%
• vasodilation 24%
• G-protein coupled receptors 12%
• vasodilator agents 12%
• cognition 12%
• mice 11%
• breast neoplasms 11%
• cholinergic agents 11%
• endothelium 10%
• rats 10%
• preserves 9%
• breasts 9%
• bones 8%
• neurons 8%
• genetically modified organisms 7%
• oxygen 7%
• glucose 6%